Dechra | Sustainability Performance
Develops and markets pharmaceuticals and related products for veterinary use.
1997
United Kingdom
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#3242
Overallⓘ#359
in United Kingdomⓘ#80
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Energy consumptionGovernance
TargetsFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Controversy level
- Dechra Pharmaceuticals plc (acquired by EQT Partners 2023 GBP 4.9 billion takeprivate), UK major veterinary pharma, has faced sustained class actions over the contested 2023 GBP 4.9 billion EQT takeprivate affecting UK institutional minority shareholders, plus periodic UK FSA enforcement scrutiny on inadequate disclosure of US/European veterinary pharma customer demand normalization affecting UK institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.